



EUROPEAN LUNG CANCER
CONFERENCE

Geneva, Switzerland
15-18 APRIL 2015

Save the date

Preliminary Programme

Wednesday, 15 April 2015

12:15-13:15 Room A	<i>Industry Satellite Symposium 1</i>	
13:15-13:40	Welcome Reception	
13:45-14:00 Room B	Opening and Welcome	Chairs: To be announced
5'	Welcome to the Conference	Dominique Grunenwald, FR and Johan Vansteenkiste, BE
5'	Intro to ESMO (President)	Rolf A. Stahel, CH
5'	Intro to IASLC (President)	Tony S.K. Mok, CN
14:00-14:30 Room B	Keynote Lecture	Chairs: To be announced
30'	The development of oncological platforms across Europe	Rolf A. Stahel, CH
14:30-16:00 Room B	Educational session Local control after treatment of early stage lung cancer	Chairs: To be announced
20'	Stereotactic ablative RT after surgical treatment	Suresh Senan, NL
20'	Surgery after stereotactic ablative RT	Paul Van Schil, BE
20'	Surgery after radiofrequency ablation	Hendrik Dienemann, DE
20'	Surgery for metachronous lung tumours	David Jones , US
10'	Questions and Answers	
14:30-16:00 Room A	Educational session The evolving role of immunotherapy for lung cancer	Chairs: To be announced
20'	Checkpoint inhibitors: State of the art	Solange Peters, CH
20'	Combination strategies	Martin Reck, DE
20'	Any room left for vaccines in lung cancer?	Johan Vansteenkiste, BE
20'	Clinical trial design and perspectives	David Carbone, US
15'	Questions and Answers	
16:00-16:30	Coffee break	

Wednesday, 15 April 2015, cont.

16:30-18:00 Room B	Educational session Mesothelioma: The rare disease that we need to know better	Chairs: To be announced
20'	Sequencing the mesothelioma genome in 2015	Giorgio Scagliotti, IT
20'	The evolving role of thoracic surgeon	Walter Weder, CH
20'	Radiotherapist: controversial role in this disease	Umberto Ricardi, IT
20'	Systemic treatment: old drugs or new approaches?	Paul Baas, NL
10'	Questions and Answers	

16:30-18:00 Room A	Educational session Toxicity management of targeted agents	Chairs: To be announced
20	Management of skin toxicity	Claude Bachmeyer, FR
20	Uncommon (cardiac, hepatic, endocrine) toxicities of targeted agents and their management	Silvia Novello, IT
20	Interactions between targeted agents and concomitant meds including life style	Ron Mathijssen, NL
20	Interaction between radiotherapy and targeted agents: Toxicity issues	Francoise Mornex, FR
10'	Questions and Answers	

18:30-19:30 Room B	Industry Satellite Symposium 2	
-----------------------	--------------------------------	--

Thursday, 16 April 2015

08:00-08:50 Room A	Multidisciplinary Interactive Session (MIS) Oncogene-driven early stage NSCLC	Chairs & Speakers
15'	Should we test for EGFR and ALK in completely resected NSCLC?	Yi Long Wu, CN
15'	How should completely resected stage II-III with activating EGFR mutation be treated? ongoing studies	Mark Kris, US
20'	Discussion	

08:00-08:50 Room X	Young Oncologists I	Chairs & Speakers
	Session content to be defined	

08:00-08:50 Room V	Multidisciplinary Interactive Session (MIS) How do we provide the best psychological care for patients with thoracic malignancies?	Chairs & Speakers
15'	The holistic approach of the patient	Jean-Louis Pujol, FR
15'	The provision of early palliative care	Thierry Berghmans, BE
20'	Discussion	

09:00-10:30 Room A	Educational session Management of neuro-endocrine tumours other than SCLC	Chairs: To be announced
20'	Radionuclide techniques for staging and treatment	Eric Baudin, FR
20'	Local therapies	Bernward Passlick, DE
20'	Systemic therapy	Simon Eckman, SE
20'	Review of a current guideline	Martyn Caplin, UK
10'	Questions and Answers	

Thursday, 16 April 2015, cont.

09:15-10:15 Room B	Controversy session Is immunotherapy a first-line treatment for NSCLC?	Chairs: To be announced
10'	Introduction and first vote	
20'	Yes	Jean-Charles Soria, FR
20'	No	Daniel Bettischer, CH
10'	Second vote and conclusions	

10:30-11:00	Coffee break
--------------------	---------------------

11:00-12:30 Room B	Specialty session How do we improve the outcome of stage III NSCLC?	Chairs: To be announced
20'	Selection of patients for multimodality treatment decision	Wilfried Eberhardt, DE
20'	Optimal staging of mediastinal lymph nodes	Christophe Doods, BE
20'	Place of neo-adjuvant or adjuvant radiotherapy	Cecile Le Pechoux, FR
20'	Improving stage III outcome: any perspective?	Paul de Leyn, BE
10'	Questions and Answers / Panel Discussion	

11:00-12:30 Room A	Specialty session Personalised radiotherapy	Chairs: To be announced
20'	The role of genetics in personalised radiotherapy	Catherine West, UK
20'	Organs at risk: How to individualise?	Dirk De Ruyscher, BE
20'	Radiomics for tumours: The future for personalised radiotherapy?	Olivier Gevaert, US
20'	How to individualise the combination of radiotherapy with drugs?	Daniel Zips, DE
10'	Questions and Answers / Panel Discussion	

11:00-12:30 Room C	Specialty session Contemporary resection techniques for stage I lung cancer	Chairs: To be announced
20'	Minimally invasive open and hybrid techniques: Morbidity and long term results	Hisao Asamura, JP
20'	Conventional VATS lobectomy/segmentectomy: Morbidity and long term results	Hendrik Hansen, DK
20'	Uniportal VATS lobectomy/segmentectomy: Morbidity and long term results	Diego Gonzales-Rivas, ES
20'	Robotic lobectomy/segmentectomy: Morbidity and long term results	Robert Cerfolio, US
10'	Questions and Answers / Panel Discussion	

11:00-12:30 Room X	Specialty session Pathology in translation	Chairs: To be announced
20'	Proliferation in lung cancer: Worth measuring?	Arne Warth, DE
20'	EQA for biomarker testing on the move	Erik Thunnissen, NL
20'	Diagnosing mesothelioma: An ongoing challenge	Andrew Churg, US
20'	Liquid biopsies: CTCs and cell-free DNA for monitoring NSCLC	Stephen Finn, IE
10'	Questions and Answers / Panel Discussion	

11:00-12:30 Room W	Specialty session The diagnostic challenge of small nodules	Chairs: To be announced
20'	Optimal follow-up of incidental nodules	Walter De Wever, BE
20'	Possibilities and limitations of endoscopy	Vincent Ninane, BE
20'	Possibilities and limitations of transthoracic procedures	Stefan Diederich, DE
20'	Can biomarkers be of help in the diagnosis?	Gabriella Sozzi, IT
10'	Questions and Answers / Panel Discussion	

Thursday, 16 April 2015, cont.

12:30-13:10	Poster lunch	
13:10-14:20 Room C	<i>Industry Satellite Symposium 3</i>	
14:30-16:00 Room B	Proffered Papers 1	
14:30-16:00 Room A	Educational session Approaches to TKI resistance	Chairs: To be announced
20'	Novel definition of TKI resistance: Clinical versus Molecular	Geoffrey Oxnard, US
20'	How to target T790M mutation?	Tony Mok, HK
20'	Management of EGFR-TKI resistance by local therapy, chemotherapy and antiangiogenesis	Martin Reck, DE
20'	Treatment options for ALK-TKI resistance	Dong Wan Kim, KR
10'	Questions and Answers	
14:30-15:30 Room V	Poster Discussion 1	
16:00-16:30	Coffee break	
16:30-18:00 Room B	Educational session Locoregional treatment for oligometastatic lung cancer	Chairs: To be announced
20'	Management of oligometastatic lung cancer and brain metastasis	Frederik Wnz, DE
20'	Surgery for oligometastatic lung cancer and liver or adrenal metastases	Paul Van Schil, BE
20'	Stereotactic ablative RT for oligometastatic lung cancer	Suresh Senan, NL
20'	Surgery for synchronous lung tumours	Giulia Veronesi, IT
10'	Questions and Answers	
16:30-18:00 Room A	Proffered Papers 2	
18:20-19:20 Room B	<i>Industry Satellite Symposium 4</i>	
18:20-19:20 Room C	<i>Industry Satellite Symposium 5</i>	
19:30	Faculty Dinner	

Friday, 17 April 2015

08:00-08:50 Room A	Multidisciplinary Interactive Session (MIS) Heterogeneity in lung cancer: The elephant in the room?	Chairs & Speakers
15'	Impact of tumour heterogeneity on biomarker testing	Yasushi Yatabe, JP
15'	Genomic heterogeneity and clonal evolution in NSCLC	Charlie Swanton, UK
20'	Discussion	

08:00-08:50 Room X	Young Oncologists session	Chairs & Speakers
	Session details to be defined	

08:00-08:50 Room W	Multidisciplinary Interactive Session (MIS) How to deal with multifocal adenocarcinoma?	Chairs & Speakers
15'	Surgical strategies and planning	Joseph Shrager, US
15'	Role of EGFR TKIs in non-metastatic multifocal adenocarcinoma	Marianne Nicolson, UK
20'	Discussion	

09:00-10:30 Room A	Educational session Functional evaluation early stage lung cancer	Chairs: To be announced
20	Cardiopulmonary function testing: What makes sense?	Alessandro Brunelli, IT
20	Preoperative risk models: The choice between surgery and stereotactic RT	Eric Lim, UK
20	Predicted postoperative lung function: How low can we go?	David Waller, UK
20	What functional evaluation before chemoradiation?	José Belderbos, NL
10'	Questions and Answers	

09:00-10:30 Room C	Proffered papers 3
-------------------------------------	---------------------------

09:15-10:15 Room B	Controversy session Can adaptive design help to proceed in clinical trials in lung cancer?	Chairs: To be announced
10'	Introduction and first vote	
20'	5 reasons pro	Benjamin Besse, FR
20'	5 reasons contra	Marc Buyse, BE
10'	Second vote and conclusions	

10:30-11:00	Coffee break
--------------------	---------------------

11:00-12:30 Room B	Specialty session Are there new targets in advanced NSCLC?	Chairs: To be announced
20'	Update of the French oncogenic platform	Fabrice Barlesi, FR
20'	Squamous carcinoma and its own targets	Roman Thomas, DE
20'	Lung cancer master protocols in the US	Fred Hirsch, US
20'	New targets relevant after the era of EGFR and ALK	Enriqueta Felip, ES
10'	Questions and Answers / Panel Discussion	

Friday, 17 April 2015, cont.

11:00-12:30 Room A	Specialty session Locally-advanced NSCLC: Addressing the challenges of large-volume disease	Chairs: To be announced
20'	Large volume LA-NSCLC disease: Definition and outcomes	Max Dahele, NL
20'	Is concurrent CT-RT superior in all large volume tumours?	Dirk De Ruyscher, BE
20'	Use of IMRT and proton therapy: Experimental or ready for prime-time?	Corinne Faivre-Finn, UK
20'	How to incorporate new agents and immunotherapy into the stage III treatment paradigm?	Rafal Dziadziusko, PL
10'	Questions and Answers / Panel Discussion	

11:00-12:30 Room C	Specialty session Approach to sulcus superior tumours	Chairs: To be announced
5'	Introduction	Dominique Grunenwald, FR
15'	Upfront surgery	Philippe Dartevelle, FR
15'	Transmanubrial approach	Hisao Asamura, JP
15'	Vertebral resection	Joachim Schirren, DE
15'	Role of systemic therapy	Egbert Smit, NL
15'	Role of radiotherapy	Paul Van Houtte, BE
10'	Discussion	

11:00-12:30 Room X	Specialty session New WHO classification: Putting it into practice	Chairs: To be announced
20'	Small biopsy and cytology diagnosis	Andrew Nicholson, UK
20'	Adenocarcinoma: What are the issues?	Bill Travis, US
20'	Tumours with squamous differentiation: What are the issues?	Ming Tsao, CA
20'	Undifferentiated tumours: What are the issues?	Keith Kerr, UK
10'	Questions and Answers / Panel Discussion	

11:00-12:30 Room W	Specialty session Quality management in thoracic oncology	Chairs: To be announced
20'	Guidelines in thoracic oncology: A European point of view	Marianne Paesmans, BE
20'	National and local care for patients with thoracic malignancies across Europe	Anna Rich, UK
20'	Quality of training in thoracic oncology: The HERMES programme	Fernando Gamarra, DE
20'	The European Initiative for Quality Management in Lung Cancer Care (EIQMLCC)	Torsten Blum, DE
10'	Questions and Answers / Panel Discussion	

1230-13:10	Poster lunch
-------------------	---------------------

13:10-14:20 Room B	<i>Industry Satellite Symposium 6</i>
-------------------------------	---------------------------------------

13:10-14:20 Room C	<i>Industry Satellite Symposium 7</i>
-------------------------------	---------------------------------------

Friday, 17 April 2015, cont.

14:30-16:00 Room C	Multidisciplinary Tumour Board How do we approach oligoprogressive disease?	Chairs: To be announced
30'	Controlled EGFR mutant disease and one rapidly growing lung nodule	Yi Long Wu, CN
30'	Crizotinib-controlled ALK positive disease and three brain metastases	Matthias Guckenberger, DE
30'	Cycle 28 pemetrexed maintenance therapy and one enlarging adrenal gland	Filippo de Marinis, IT

14:30-15:30 Room V	Poster Discussion 2
-------------------------------	----------------------------

16:30-18:00 Room B	ESMO-IASLC Best Abstracts	Chairs: To be announced
	Session details to be defined	

16:30-18:00 Room A	Educational session Expanding the role of biomarkers	Chairs: To be announced
20'	Biomarker testing beyond EGFR and ALK: Expanding the list of tests	Caicun Zhou, CN
20'	Biomarker testing on cytology samples	Lukas Bubendorf, CH
20'	Biomarker testing: Challenges in delivering the service	Fred Hirsch, US
20'	NGS techniques: Ready for 'prime time'?	Reinhard Büttner, DE
10'	Questions and Answers	

Saturday, 18 April 2015

08:00-08:50 Room X	Multidisciplinary Interactive Session (MIS) Complex non T3 –T4 and non N2 resectable disease	Chairs & Speakers
15'	Pathological N1 disease: Extent of resection	David Waller, UK
15'	Invasion across the fissure: Extent of resection	Pascal Thomas, FR
20'	Discussion	

08:00-08:50 Room V	Multidisciplinary Interactive Session (MIS) Survivorship issues after stereotactic ablative RT for early-stage NSCLC	Chairs & Speakers
15'	Predicting survival following SABR in early-stage NSCLC	Umberto Ricardi, IT
15'	Treatment of disease detected post-SABR	Gaetano Rocco, IT
20'	Discussion	

09:00-10:30 Room B	Educational session Screening and early detection	Chairs: To be announced
20'	Chemoprevention of lung cancer	Andrea De Censi, IT
20'	Molecular markers for early detection	Fabrizio Bianchi, IT
20'	Update on European lung cancer screening randomised and non-randomised studies	Nanda Horeweg, NL
20'	Update on Asian lung cancer screening randomised and non-randomised studies	Ryutaro Kakinuma, JP
10'	Questions and Answers	

Saturday, 18 April 2015, cont.

09:00-10:30 Room C	Educational session Refining Radiation Therapy for SCLC	Chairs: To be announced
20'	Radiobiology of SCLC and implications for treatment and research	Rebecca Bütof, DE
20'	Up-date Time-Dose-Fractionation-Schedule for thoracic radiochemotherapy in limited disease	Jose Belderbos, NL
20'	Indications, efficacy and toxicity of PCI in limited and extensive disease	Cecile Le Pechoux, FR
20'	Thoracic radiation therapy for extensive disease	Ben Slotman, NL
10'	Questions and Answers	

10:30-11:00 Room B	ELCC Award Lecture	Chairs: To be announced
	Session details to be defined	

11:00-11:20	Coffee break
--------------------	--------------

11:20-12:50 Room B	Educational session Smoking epidemiology and smoking cessation techniques	Chairs: To be announced
20'	Molecular susceptibility for lung cancer and nicotine addiction	Gerard Zalcman, FR
20'	Smoking cessation in screening programmes	Paolo Boffetta, US
20'	Smoking cessation in young people	Anneke Bühler, DE
20'	Do electronic cigarettes impact on smoking cessation?	Elisabeth Quoix, FR
10'	Questions and Answers	

11:20-12:50 Room C	Educational session The proper treatment algorithm for non-oncogene driven NSCLC	Chairs: To be announced
20'	Optimal first line treatment	Kostas Syrigos, GR
20'	Treatment of the relapsed patient	Anne-Marie Dingemans, NL
20'	Chemotherapy for patients with brain metastases	Stefan Zimmermann, CH
20'	Future direction: Pharmacogenomics or new chemotherapeutic agents?	Giorgio Scagliotti, IT
10'	Questions and Answers	

12:50-13:00 Room B	Closing remarks	Chairs: Dominique Grunenwald, FR and Johan Vansteenkiste, BE
-------------------------------------	------------------------	---